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Abstract
Purpose: To determine the differentiating features between non-hypervascular pancreatic neuroendocrine tumour 
(PNET) and pancreatic ductal adenocarcinoma (PDAC) on dynamic computed tomography (CT) and non-enhanced 
magnetic resonance imaging (MRI).
Material and methods: We enrolled 102 patients with non-hypervascular PNET (n = 15) or PDAC (n = 87), who had 
undergone dynamic CT and non-enhanced MRI. One radiologist evaluated all images, and the results were subjected 
to univariate and multivariate analyses. To investigate reproducibility, a second radiologist re-evaluated features that 
were significantly different between PNET and PDAC on multivariate analysis.
Results: Tumour margin (well-defined or ill-defined) and enhancement ratio of tumour (ERT) showed significant 
differences in univariate and multivariate analyses. Multivariate analysis revealed a predominance of well-defined tu-
mour margins in non-hypervascular PNET, with an odds ratio of 168.86 (95% confidence interval [CI]: 10.62-2685.29; 
p < 0.001). Furthermore, ERT was significantly lower in non-hypervascular PNET than in PDAC, with an odds ratio of 
85.80 (95% CI: 2.57-2860.95; p = 0.01). Sensitivity, specificity, and accuracy were 86.7%, 96.6%, and 95.1%, respectively, 
when the tumour margin was used as the criteria. The values for ERT were 66.7%, 98.9%, and 94.1%, respectively. In 
reproducibility tests, both tumour margin and ERT showed substantial agreement (margin of tumour, κ = 0.6356; ERT, 
intraclass correlation coefficients (ICC) = 0.6155).
Conclusions: Non-hypervascular PNET showed well-defined margins and lower ERT compared to PDAC, with signif-
icant differences. Our results showed that non-hypervascular PNET can be differentiated from PDAC via dynamic 
CT and non-enhanced MRI.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of 
the most aggressive cancers. It has a poor prognosis, and 
the five-year survival rate is less than 4% [1-3]. This high 
mortality rate is due to the cancer’s biological aggressive-
ness and advanced state at the time of diagnosis [4]. In 
recent years, the incidence of PDAC has been increasing, 
and it is projected to be the second most common cause 
of cancer-related death in the United States in 2020 [5].
Meanwhile, pancreatic neuroendocrine tumour (PNET) 
is a rare pancreatic tumour originating from pluripotent 
stem cells in the ductal epithelium [2,6]. PNET is patho-
logically classified into G1, G2, and G3 according to Ki-67 
index. G1 and G2 indicate well-differentiated PNET, and 
G3 indicates a poorly differentiated neuroendocrine carci-
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noma [7]. The five-year survival rate ranges from 60-100% 
for well-differentiated PNET to 29% for poorly differen-
tiated PNET [8]. 
Surgery is the only curative treatment for patients 
with PNET or PDAC. Patients with PDAC need a more 
radical surgery that includes lymphadenectomy [4,9,10], 
while those with PNET, which is non-invasive and smaller 
in size (< 20 mm), may only require a limited resection 
without lymphadenectomy, such as tumour enucleation, 
central pancreatectomy, or laparoscopic surgery [10]. 
Therefore, it is important to differentiate between PNET 
and PDAC preoperatively to estimate the prognosis and 
plan a surgical strategy.
PNET usually shows arterial enhancement with pro-
gressively decreased enhancement [2,3,6,11]. Although 
clinicians can easily diagnose PNET on preoperative im-
aging because, other than PNET, the number of hypervas-
cular pancreatic tumours is very small [11], up to 48.6% of 
PNET does not show arterial enhancement, as is common 
in most PDAC [9,12,13]. Therefore, non-hypervascular 
PNET can be a differential diagnosis during assessment 
for PDAC via imaging.
Only a few studies have focused on the differences 
between non-hypervascular PNET and PDAC found on 
diagnostic images. The purpose of this study was to eval-
uate the findings on dynamic computed tomography (CT) 
and non-enhanced magnetic resonance imaging (MRI) 
for differentiation between non-hypervascular PNET and 
PDAC.
Material and methods
Patient selection
This retrospective cohort study was approved by the review 
board of our institution, and the need for informed con-
sent was waived. The records of the patients with patholog-
ically proven PNET or PDAC were reviewed when clinical 
information was available. All patients underwent surgery, 
including pancreatoduodenectomy, distal pancreatectomy, 
central pancreatectomy, and tumour enucleation, between 
April 2011 and June 2017. According to the European 
Society for Medical Oncology (ESMO) Clinical Practice 
Guidelines, dynamic CT plays a central role in the evalua-
tion of pancreatic tumour, especially when pancreatic can-
cer is suspected, and should be the first choice of imaging 
investigation [14]. Furthermore, MRI could be useful as 
a supplementary imaging modality to evaluate vessel in-
volvement and biliary anatomy, detect liver metastasis not 
detected by CT, and differentiate cystic lesions [14]. Based 
on the literature, we evaluated pancreatic tumours with 
dynamic CT and non-enhanced MRI. The inclusion crite-
ria were as follows: (a) patients who underwent dynamic 
CT and non-enhanced MRI according to our institution-
al routine protocol within six months before surgery and 
(b) patients who had a detectable tumour, and the region 
of interest (ROI) could be set via CT and MRI. Meanwhile, 
the exclusion criteria were patients who had tumours with 
visually higher enhancement than pancreatic parenchyma 
on arterial phase.
CT scanning protocol
All CT images were obtained using either a 64-channel 
scanner (SOMATOM Perspective, Siemens, n = 34) or 
a 128-channel scanner (SOMATOM Definition Flash, 
n = 32 or SOMATOM Definition AS+, Siemens, n = 36). 
The scanning protocol consisted of non-enhanced and 
biphasic contrast-enhanced scans. The non-enhanced 
phase was obtained through the upper abdomen, in-
cluding the entire liver and pancreas. Then, a bolus of 
600 mgI/kg of iodine contrast medium was administered 
using an automatic power injector at a rate of 2.0-3.0 ml/s 
for 33 seconds. The contrast media used included iohex-
ol (Omnipaque 350 Injection, Daiichi Sankyo, n = 34 or 
IOVERIN 350, Teva Takeda Pharma, n = 25), iopamidol 
(Iopamiron 370 Inj., Bayer Yakuhin, n = 20 or Oypalomin 
370 injection, Fuji Pharma, n = 18), or iomeprol (Iomeron 
350, Eisai, n = 5). Arterial phase was obtained 10 seconds 
after reaching 80 Hounsfield units with the ROI placed 
on the aorta at the level of the celiac artery, while portal 
venous phase was obtained 90 seconds after triggering. 
The arterial and portal venous phases were obtained 
through the upper abdomen and through the whole ab-
domen, respectively.
MRI scanning protocol
All MRI images were acquired using a 1.5-T whole-body 
MRI system with a six-channel phased array as the re-
ceiver coil (MAGNETOM Avanto, Siemens, n = 43 or 
MAGNETOM Symphony, A Tim System, Siemens, 
n = 59). The following objects were analysed in the routine 
abdominal MRI protocol: transverse T1-weighted image 
(T1WI) using a fat-saturated 2D or 3D gradient echo 
(2D fast low-angle shot or 3D volumetric interpolat-
ed breath-hold sequence; transverse T2-weighted im-
age (T2WI) with fast spin-echo; and transverse diffu-
sion-weighted image (DWI) performed as a single-shot 
echo-planar imaging pulse sequence with b-values of 
50 and 800 sec/mm2 using respiratory triggering. The ap-
parent diffusion coefficient (ADC) was calculated with b 
values of 50 and 800 sec/mm2. The MRI pulse sequence 
parameters are summarised in Table 1.
Imaging analysis
An abdominal radiologist with 11 years of experience, 
who was blinded to pathological diagnosis and clinical in-
formation, retrospectively reviewed anonymised dynamic 
CT and non-enhanced MRI images on a Picture Archiv-
ing and Communication Systems workstation monitor.
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For qualitative analysis, the following imaging param-
eters were evaluated: (a) tumour margin (well-defined or 
ill-defined), (b) cystic change or necrosis (present or ab-
sent), (c) calcification (present or absent), (d) upstream 
pancreatitis (present or absent), and (e) dilated main pan-
creatic duct (present or absent). Upstream pancreatitis 
was defined as pancreatic parenchyma showing high in-
tensity on DWI and low intensity on fat-saturated T1WI. 
The dilated main pancreatic duct was defined as positive 
when its diameter was more than 3 mm. Pancreatic pa-
renchyma was defined as a presumed non-pathological 
pancreatic region in which focal abnormalities such as 
pancreatitis and/or cystic lesions were not included.
For quantitative analysis, the following parameters 
were evaluated: (a) tumour size, (b) CT attenuation and 
MRI signal intensity of tumour and pancreatic parenchy-
ma, (c) ADC values of tumour, (d) CT attenuation and 
MRI signal intensity ratios of tumour to pancreatic paren-
chyma, and (e) enhancement ratio of tumour (ERT). ROI 
was set to the largest solid portion of the tumour, avoiding 
the cystic component on CT images of non-enhanced, ar-
terial phase, and portal venous phase, and on MRI images 
of fat-saturated T1WI, T2WI, DWI, and ADC map. We 
measured the density and signal intensity three times by 
ROI, and the average value was calculated. The CT atten-
uation and MRI signal intensity ratios of tumour to pan-
creatic parenchyma were calculated using the following 
formula: mean CT attenuation or MRI signal intensity 
of tumour/mean CT attenuation or MRI signal intensity 
of pancreatic parenchyma. The ERT during arterial and 
portal venous phases were calculated as follows: (Tp-Ta)/
(Ta-Tn), where Tn, Ta, and Tp were the attenuation of the 
tumour in Hounsfield units, measured during non-en-
hanced, arterial, and portal venous phase, respectively.
To assess the reproducibility of significant variables, 
a second radiologist with three years of experience in 
abdominal imaging evaluated variables that showed sig-
nificant differences on multivariate analyses, while being 
blinded to the pathological and clinical information.
Statistical analysis
Fisher’s exact test was used for qualitative variables, and 
the Mann-Whitney U test was used for quantitative analy-
sis. Multivariate logistic regression analysis was performed 
using variables estimated to be related to outcomes based 
on knowledge and clinical judgment from previous re-
ports [6,10,11,13].
The diagnostic performance of each quantitative var-
iable was estimated via receiver operating characteristic 
(ROC) analysis. The optimal thresholds for differentiat-
ing between the PNET group and the PDAC group were 
chosen at the highest possible sensitivity and specificity 
on the ROC curves. Variables set with optimal thresholds 
were fit to the multivariate logistic regression analysis. 
Statistical analysis was executed using Ekuseru-Toukei 
2015 (SSRI, Tokyo, Japan) and R (The R Project for Sta-
tistical Computing, version 3.3.0). For all tests, a p-value 
of less than 0.05 was considered statistically significant. 
Inter-observer agreement of findings was evaluated by cal-
culating κ values for dichotomous variables or intraclass 
correlation coefficients (ICC) for continuous variables. 
The κ values and ICC were classified as follows: 1.0 was 
considered to indicate perfect agreement; 0.81-0.99, almost 
perfect agreement; 0.61-0.80, substantial agreement; 0.41-
0.60, moderate agreement; 0.21-0.40, fair agreement; and 
≤ 0.20, slight agreement.
Results
A total of 102 patients (15 patients with non-hypervascu-
lar PNET and 87 patients with PDAC) met the inclusion 
Table 1. Pulse sequence parameters for 1.5-T MR imaging
Factor 2D FLASH 3D VIBE T2WI DWI
TR (ms) 102-142 4.94-5.20 3000 1200-1500
TE (ms) 4.76-5.04 1.86-1.93 90-91 67-86
FA (degrees) 70 15.0 150
b values 50/800
Matrix 187 × 256 199 × 384 208 × 320-256 × 320 77 × 128
FOV 308 × 380-308 × 384 300 × 400 308 × 380 262 × 350-277 × 370
ST (mm) 7.0 3.0 7.0 7.0
BW (Hz/pixel) 300 260 601 1346-2298
AT (s) 38 19-20 30 2:09-2:26
ETL 31
FLASH – fast low-angle shot, VIBE – volumetric interpolated breath-hold examination (T1-weighted gradient-echo sequences, which are referred  
to as “FLASH” and “VIBE” on Siemens Healthcare MRI systems), T2WI – T2-weighted imaging, DWI – diffusion-weighted imaging, TR – repetition time, 
TE – echo time, FA – flip angle, FOV – field of view, ST – slice thickness, BW – bandwidth, AT – acquisition time, ETL – echo train length, MR – magnetic 
resonance
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criteria (Figure 1). All included patients each had one le-
sion. No patients with hypervascular PDAC were identi-
fied. The cohort consisted of 58 men and 44 women, with 
an average age of 66 years (range: 31-84 years). The sur-
geries performed in this study were pancreatoduodenec-
tomy, distal pancreatectomy, central pancreatectomy, 
and tumour enucleation; the breakdown was as follows: 
3 (20%), 7 (47%), 3 (20%), and 2 (13%) patients with 
PNET and 51 (59%), 36 (41%), 0, and 0 patients with 
PDAC underwent such surgeries, respectively. Based on 
the 2010 World Health Organisation classification system, 
of 15 PNETs, five tumours (33.3%) were classified as G1, 
eight (55.3%) were classified as G2, and two (13.3%) were 
classified as G3.
The results of patient and tumour characteristic 
analyses are summarised in Table 2. The mean ROI of 
the tumours was 121.5 ± 88.5 mm2. Age and tumour 
size showed significant differences. PNET patients were 
younger (p < 0.001), and their tumour sizes were smaller 
than those of PDAC patients (p = 0.04).
The results of quantitative and qualitative assessments 
are presented in Table 3. The well-defined margin was 
significantly different between non-hypervascular PNET 
and PDAC (p < 0.001). Only two PNETs (13.3%) showed 
ill-defined margin. These two tumours were poorly dif-
ferentiated neuroendocrine carcinomas classified as his-
topathological G3. The remaining 13 tumours were G1 or 
G2. The absence of both upstream pancreatitis and dilat-
ed main pancreatic duct was significant between non-hy-
pervascular PNET and PDAC (p < 0.001) (Figures 2-4). 
On univariate analysis, CT attenuation ratio of tumour 
to pancreatic parenchyma on arterial phase (p < 0.001) 
and ERT (p < 0.001) showed a significant difference, but 
CT attenuation ratio of tumour to pancreatic parenchyma 
on portal venous phase did not (p = 0.05). MRI signal 
intensity ratio of tumour to pancreatic parenchyma on all 
sequences and ADC also did not show a significant differ-
ence on univariate analysis.
The results of multivariate analyses are summarised 
in Table 4. There was a significant difference in tumour 
margin between PNET and PDAC (odds ratio: 168.86; 
95% confidence interval [CI]: 10.62-2685.29; p < 0.001). 
ERT was also significantly different between groups (odds 
ratio: 85.80; 95% CI: 2.57-2860.95; p = 0.01). Although 
not significant, the quantitative assessment of CT attenua-
tion ratio of tumour to pancreatic parenchyma on arterial 
phase showed relatively good discriminative performance 
on multivariate analyses (odds ratio: 5.31; 95% CI: 0.40-
71.17; p = 0.21). The sensitivity, specificity, and accuracy 
of tumour margin was 86.7%, 96.6%, and 95.1%, respec-
tively, while it was 66.7%, 98.9%, and 94.1%, respectively, 
for ERT.
The results of reproducibility tests of significant varia-
bles showed that the κ value for tumour margin was 0.64, 
PNET – pancreatic neuroendocrine tumour, PDAC – pancreatic ductal adenocarcinoma, MR – magnetic resonance
Pathologically proven PNET patients (n = 30)
One patient had 2 lesions (31 lesions)
Excluded PNET patients (n = 4) for
– incomplete image data (n = 1)
– other hospital image data (n = 1)
– having multiple tumours (n = 1)
– unclear lesion in MR image (n = 1)
Non-hypervascular PNET patients (n = 15)
Hypervascular PNET patients (n = 11)
One patient had 2 lesions (12 lesions)
PDAC patients (n = 87) 
87 PDAC patients (n = 87)
Excluded PDAC patients (n = 13) for
– incomplete image data (n = 6)
– other hospital image data (n = 3)
– image date > 6 months before surgery (n =3)
– unsatisfactory imaging quality (n = 1)
Pathologically proven PDAC patients (n = 100)
Figure 1. Flow diagram summarising the patient sampling process
PNET patients (n = 26)
One patient had 2 lesions (27 lesions)
Table 2. Results of patient and tumour characteristics
Variable PNET (n = 15) PDAC (n = 87) p-value
Age (y) 51 (42-63.5) 69 (63-76) < 0.001
Gender
Male 8 (53) 50 (57) 0.78
Female 7 (47) 37 (43)
Tumour location
Head 3 (20) 50 (57) 0.01
Body 9 (60) 21 (24)
Tail 3 (20) 16 (18)
Tumour size (mm) 16 (13-25.5) 25 (18.5-33) 0.04
Numbers in parentheses are percentages.
Age and size are expressed as median and interquartile range (25-75 percentile).
PNET – pancreatic neuroendocrine tumour, PDAC – pancreatic ductal adenocarcinoma
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and the ICC for ERT was 0.62. Both results were in sub-
stantial agreement.
Discussion
We evaluated the findings of dynamic CT and non-en-
hanced MRI that contributed to differentiation between 
non-hypervascular PNET and PDAC. We also conducted 
blinded observer tests to assess the reproducibility of such 
imaging findings.
Our results showed that there was a significant differ-
ence in well-defined margins between non-hypervascular 
PNET and PDAC (p < 0.001). These results were similar 
to previous studies that reported the same morphological 
tendency of hypervascular PNET [6,10,11]. The presence 
of well-defined margins was also a useful feature for dif-
ferentiating between PDAC and PNET, even when exclu-
sive to the non-hypervascular type, when dynamic con-
trast enhancement was inconclusive. Additionally, in our 
study, tumours with ill-defined margins were either PDAC 
or non-hypervascular G3 PNET. Although G3 PNET was 
identified in two cases, these results could also indicate 
that radical surgery should be considered if a patient pre-
sents with a pancreatic tumour with an ill-defined margin 
on preoperative imaging, because it increases the possibil-
ity of non-hypervascular G3 PNET or PDAC.
Our results show that ERT of non-hypervascular 
PNET is significantly lower than that of PDAC. ERT is 
considered to be affected by the degree of tumour fibro-
sis because abundant fibrosis reduces blood inflow to 
the tumour [15]. Histologically, PNET shows a lower 
degree of fibrosis, while PDAC shows abundant internal 
Table 3. Results of quantitative and qualitative assessment
Variable PNET (n = 15) PDAC (n = 87) p-value
Tumour margin
Well-defined 13 (87) 3 (3) < 0.001
Ill-defined 2 (13) 84 (97)
Cystic change or necrosis
Absent 12 (80) 62 (71) 0.75
Present 3 (20) 25 (29)
Calcification
Absent 13 (87) 82 (94) 0.27
Present 2 (13) 5 (6)
Upstream pancreatitis
Absent 14 (93) 41 (47) < 0.001
Present 1 (7) 46 (53)
Dilated main pancreatic duct
Absent 13 (87) 25 (29) < 0.001
Present 2 (13) 62 (71)
Non-enhanced phasea 0.881 (0.791-0.930) 0.897 (0.755-1.000) 0.59
Arterial phasea 0.866 (0.650-1.066) 0.585 (0.508-0.645) < 0.001
Portal venous phasea 1.013 (0.898-1.233) 0.921 (0.791-1.062) 0.05
Enhancement ratio of tumour (ERT)b 0.000 (–0.152-0.701) 1.000 (0.681-1.433) < 0.001
Fat-saturated T1-weighted imagea 0.649 (0.540-0.777) 0.665 (0.596-0.752) 0.80
T2-weighted imagea 1.279 (1.049-1.493) 1.190 (1.052-1.387) 0.62
Diffusion-weighted imagea 1.577 (1.409-1.941) 1.500 (1.220-1.860) 0.44
ADC (×10-3 mm2/sec) 1.214 (1.010-1.437) 1.283 (1.159-1.412) 0.40
aCT attenuation or MR signal intensity ratio of tumour to pancreatic parenchyma
bEnhancement ratio of tumour = (Tp – Ta)/(Ta – Tn)
Numbers in parentheses are percentages.
Tn, Ta, and Tp are the attenuation of tumour (in Hounsfield Units) during non-enhanced, arterial, and portal venous phase measured, respectively.
Continuous variables are expressed as median and interquartile range (25-75 percentile).
PNET – pancreatic neuroendocrine tumour, PDAC – pancreatic ductal adenocarcinoma, ADC – apparent diffusion coefficient, CT – computed tomography, MR – magnetic resonance
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Figure 2. Imaging results from a 36-year-old man with non-hypervascular pancreatic neuroendocrine tumour (PNET) in the body of the pancreas. 
A) Fat-saturated T1-weighted image shows well-defined hypointense lesion (arrow). B) The enhanced portal venous phase computed tomography image 
shows iso-enhancement of the lesion relative to the adjacent parenchyma; therefore, the lesion is difficult to detect (circle) (C) and (D). The enhanced arterial 
phase computed tomography image shows that the lesion is hypoenhanced relative to the adjacent parenchyma and well-defined (arrow)
A
C
B
D
fibrosis [12,16]. As such, it is assumed that non-hyper-
vascular PNET shows lower ERT than PDAC. ERT is not 
affected by attenuation changes of the surrounding pan-
creatic parenchyma caused by tumour-induced pancrea-
titis, and it could be calculated using only the attenuation 
of the tumour. Therefore, the use of ERT is valuable in 
differentiating between PNET and PDAC. Jeon et al. [13] 
reported that hyper- or iso-enhancement in the portal 
venous phase are useful for differentiating between 
non-hypervascular PNET and PDAC. They also reported 
a line chart analysis of temporal contrast-to-noise ratio 
(CNR), which is the enhancement ratio of the tumour ad-
justed by the paraspinal muscle for standardisation [13]. 
The line chart analysis of temporal CNR of PDAC showed 
a higher rate of contrast enhancement over time than 
that of non-hypervascular PNET. This was similar to our 
results that showed a lower ERT on non-hypervascular 
PNET and a higher ERT on PDAC. Our results on ERT 
also supported their results in the line chart analysis of 
temporal CNR as a dynamic curve. However, our results 
cannot be directly compared to their results because our 
CT acquisition times for arterial and portal venous phases 
were different from those used in their protocol, and we 
used ERT as a variable, rather than a dynamic curve.
The CT attenuation ratio of tumour to pancreatic 
parenchyma on arterial phase showed a relatively good 
discriminative performance on multivariate analyses, 
although not significant (p = 0.21). This could indicate 
that non-hypervascular PNET shows a substantially high-
er enhancement degree compared with PDAC in arterial 
phase on quantitative analysis, even though both non- 
hypervascular PNET and PDAC showed a similar internal 
enhancement in arterial phase on visual assessment. This 
may reflect that the inherent histopathological property 
of the rich capillary network of PNET is associated with 
vascularity in the arterial phase [6].
A previous study by d’Assignies et al. showed that the 
blood flow of PNET is related to its grade, and that blood 
flow was significantly higher in the group of benign tu-
mours [17]. In our study, 86.7% (13/15) of tumours were 
low-grade tumours classified as G1 or G2. Although 
excluded from this study, all hypervascular PNET were 
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Figure 3. Imaging results from a 41-year-old man with non-hypervascular pancreatic neuroendocrine tumour (PNET) in the body of the pancreas. A) Fat- 
saturated T1-weighted image shows well-defined hypointense lesion (arrow). B) The enhanced portal venous phase computed tomography image shows 
weak enhancement of the adjacent parenchyma (arrow) (C) and (D). The enhanced arterial phase computed tomography image shows iso-enhancement 
of the lesion relative to the adjacent parenchyma; therefore, the lesion is difficult to detect (circle)
A
C D
B
low-grade tumours; of 12 tumours, 11, 1, and 0 were G1, 
G2, and G3, respectively. Our results agreed with those of 
d’Assignies et al., as the proportion of G2 and G3 tumours 
increased in non-hypervascular PNET compared to the 
hypervascular PNET. However, 86.7% of tumours among 
non-hypervascular PNET were low-grade tumours. More-
over, our results were similar to findings of a study by Jeon 
et al., in which low-grade tumours accounted for 89% of 
non-hypervascular PNET [13]. Although non-hypervas-
cular PNET is more likely than hypervascular PNET to 
include high grade tumours, the majority of non-hyper-
vascular PNET are low-grade tumours that require less 
extensive surgery; thus, it is clinically important to differ-
entiate non-hypervascular PNET from PDAC.
Little is known about the added value of non-enhanced 
MRI for differentiation between PNET and PDAC. In 
our study, the signal intensity of MRI including DWI and 
ADC showed no significant difference between PNET 
and PDAC. Such a result was similar to previous reports 
[11,18]. Concerning PNET, some studies showed that 
DWI and ADC have predictive value for tumour grading. 
This is particularly useful to differentiate between G1-2 
and G3 tumours [19-21].
The limitations of our study are its single-site ret-
rospective design and the higher number of PDAC pa-
tients than non-hypervascular PNET. Non-hypervascular 
PNET is the less frequent type of PNET, which is generally 
a rare tumour, and only 15 cases of non-hypervascular 
PNET were seen in our study. Future studies with larger 
sample sizes are required to provide additional accuracy 
to our study. Furthermore, our study included all grades 
of PNET. Some previous studies reported that DWI is use-
ful for the differentiation between G1-2 and G3 tumours 
[19-21]. Thus, if we subdivide the cases into different 
grades of PNET (G1-3) and PDAC prior to evaluation, 
there may be some imaging features that can differentiate 
these tumours. Additionally, our arterial phase protocol 
was conducted earlier than recommended in the Euro-
pean Society for Medical Oncology (ESMO) Clinical 
Practice Guidelines [4,14]. In our CT imaging protocol, 
the arterial phase was taken 10 seconds after reaching 
80 Hounsfield units with ROI placed on the aorta. This 
Kazuyoshi Ohki, Takao Igarashi, Hirokazu Ashida et al.  
e160 © Pol J Radiol 2019; 84: e153-e161
Figure 4. Imaging results from a 67-year-old man with pancreatic ductal 
adenocarcinoma (PDAC) in the uncinate process of the pancreas. A) The en-
hanced arterial phase and (B) portal venous phase computed tomography 
images show an ill-defined hypovascular lesion (arrow). C) The fat-satu-
rated T1-weighted image shows a hypointense ill-defined lesion (arrow). 
The lesion invades beyond the superior mesenteric artery to the left side 
outside of the pancreas
A
C
B
was approximately 30 seconds after administration of 
the contrast agent, which is earlier than the 40 seconds 
recommended in the ESMO Clinical Practice Guidelines. 
The pancreatic arterial phase should also be acquired to 
better compare CT imaging findings to previous reports.
In conclusion, a well-defined margin and a lower ERT 
of non-hypervascular PNET contributed to differentiation 
between non-hypervascular PNET and PDAC. Conse-
quently, by interpreting the images correctly, unnecessary 
extensive surgery can be avoided.
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Table 4. Results of multivariate analysis
Variable Odds ratio 95% CI p-value
Tumour margin (well-defined vs. ill-defined) 168.86 10.62 2685.29 < 0.001
CT attenuation ratio of tumour to pancreatic parenchyma on arterial phase (≥ 0.64 vs. < 0.64) 5.31 0.40 71.17 0.21
Enhancement ratio of tumour (ERT)a (≤ 0.25 vs. > 0.25) 85.80 2.57 2860.95 0.01
aEnhancement ratio of tumour = (Tp – Ta)/(Ta – Tn)
Tn, Ta, and Tp are the attenuation of tumour (in Hounsfield Units) during non-enhanced, arterial, and portal venous phase measured, respectively.
CI – confidence interval, ERT – enhancement ratio of tumour, CT – computed tomography
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